Andres-Mateos, Eva
Landegger, Lukas D. http://orcid.org/0000-0002-9660-2625
Unzu, Carmen
Phillips, Jean
Lin, Brian M.
Dewyer, Nicholas A. http://orcid.org/0000-0003-0350-7483
Sanmiguel, Julio
Nicolaou, Fotini
Valero, Michelle D.
Bourdeu, Kathrin I.
Sewell, William F.
Beiler, Rudolph J.
McKenna, Michael J.
Stankovic, Konstantina M. http://orcid.org/0000-0003-0233-279X
Vandenberghe, Luk H. http://orcid.org/0000-0002-3508-4924
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (R01DC015824)
Nancy Sayles Day Foundation (n/a)
Lauer Tinnitus Research Center, Massachusetts Eye and Ear (n/a)
Article History
Received: 12 March 2021
Accepted: 14 February 2022
First Online: 15 March 2022
Competing interests
: L.H.V. is an inventor on several patents related to AAV gene therapy, including Anc80L65, AAV9, and method patents, which are licensed to several biopharma companies. During these studies, L.H.V. further receives funding from Lonza/Houston, Selecta Biosciences, and Solid Biosciences, which all had a licensing interest in the AncAAV technology. L.H.V. is a consultant and founder of Akouos, a hearing gene therapy company that has licensed the Anc80L65 technology. L.H.V. has a financial interest in Affinia, a company developing AAV gene therapies; he is an inventor of technology related to AAV gene therapy, a founder of the company, and also serves on its Board of Directors. L.H.V.’s interests were reviewed and are managed by M.E.E. and Partners HealthCare in accordance with their conflicts of interest policies. E.A.M., J.P., B.M.L., M.D.V. are employees at Akouos, Inc.; W.F.S. is a founder of Akouos, Inc.; M.J.M. is a founder and employee at Akouos, Inc. The other authors declare no competing interests.